Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Review and Preview01:10

Review and Preview

8.3K
In statistics, several tools are used to interpret the data. Measures of central tendency represent the characteristics of the data, such as mean, median, and mode. Additionally, measures of variance like standard deviation and range are used to find the spread of data from the mean. Relative standing measures the distance between data locations. Commonly used measures of relative standings are percentile, z score, and quartiles.
Percentiles are a type of fractile that partition data into...
8.3K
Review and Preview01:13

Review and Preview

11.0K
Data are individual items of information obtained from a population or sample. Data may be classified as qualitative (categorical), quantitative continuous, or quantitative discrete. Because it is not practical to measure the entire population in a study, researchers use samples to represent the population. A random sample is a representative group from the population chosen by using a method that gives each individual in the population an equal chance of being included in the sample. Random...
11.0K
Ethics in Research01:56

Ethics in Research

25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effects of Iron Overload on the Apoptosis and Function of Splenic CD8+ T Cells in Mice].

Zhongguo shi yan xue ye xue za zhi·2016
Same author

Symptom Frequencies and Intensities in Hospitalized Patients With Advanced Cancer Having Depressive Disorder.

The American journal of hospice & palliative care·2016
Same author

A novel PPARα agonist propane-2-sulfonic acid octadec-9-enyl-amide inhibits inflammation in THP-1 cells.

European journal of pharmacology·2016
Same author

A modified procedure for lumbar intrathecal catheterization in rats.

Neurological research·2016
Same author

Characteristics and Distribution of Phosphorus in Surface Sediments of Limnetic Ecosystem in Eastern China.

PloS one·2016
Same author

N-Oleoylethanolamine Reduces Inflammatory Cytokines and Adhesion Molecules in TNF-α-induced Human Umbilical Vein Endothelial Cells by Activating CB2 and PPAR-α.

Journal of cardiovascular pharmacology·2016

Related Experiment Video

Updated: Jan 27, 2026

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy
05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

820

[Lenalidomide in hematological malignancies---review].

Xin Jin1, Yi-Zhuo Zhang

  • 1Department of Hematology, Tianjin Medical University Tumor Hospital, Tianjin, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|March 7, 2012
PubMed
Summary

Lenalidomide shows efficacy in treating various hematologic malignancies, including multiple myeloma and myelodysplastic syndromes. Further research explores its potential in other blood cancers like lymphoma and leukemia.

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Lenalidomide, a thalidomide analog, exhibits immunomodulatory and antiangiogenic properties.
  • It is approved for multiple myeloma and myelodysplastic syndromes, demonstrating significant efficacy.
  • Emerging evidence suggests lenalidomide's potential in other hematologic malignancies.

Purpose of the Study:

  • To review current studies on lenalidomide's efficacy in hematologic malignancies.
  • To highlight recent advancements and progression in lenalidomide treatment.
  • To provide references for lenalidomide's clinical application in blood cancers.

Main Methods:

  • Literature review of studies investigating lenalidomide in hematologic malignancies.
  • Analysis of data on lenalidomide's mechanisms of action, including cytotoxicity and immune effects.

More Related Videos

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

11.3K

Related Experiment Videos

Last Updated: Jan 27, 2026

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy
05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

820
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

11.3K
  • Evaluation of clinical trial outcomes for various blood cancers.

    • Main Results:

    • Lenalidomide demonstrates durable responses and manageable adverse events in non-Hodgkin's lymphoma, relapsed/refractory Hodgkin's lymphoma, chronic lymphocytic leukemia, and older acute myeloid leukemia patients.
    • Mechanisms include direct cytotoxicity and indirect modulation of tumor immunity.
    • The drug's efficacy warrants further investigation across a broader spectrum of hematologic malignancies.

    Conclusions:

    • Lenalidomide is a promising therapeutic agent for a range of hematologic malignancies beyond its current approved indications.
    • Continued research is essential to fully elucidate its role and optimize treatment strategies.
    • Lenalidomide offers a valuable option for patients with relapsed/refractory hematologic cancers.